2025
Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms
Ramanathan R, Xie Y, Badar T, Zeidan A, Patel S. Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms. British Journal Of Haematology 2025, 206: 1571-1581. PMID: 40302714, DOI: 10.1111/bjh.20116.Peer-Reviewed Original ResearchConceptsInvestigational therapiesTraditional erythropoiesis-stimulating agentsContemporary treatment optionsMulticentre randomized trialSubsets of patientsErythropoiesis-stimulating agentsResponse to therapeuticsFood and Drug AdministrationU.S. Food and Drug AdministrationClinical trial designHypomethylating agentsMutated TP53Treatment landscapeComprehensive genomic sequencingTreatment optionsRandomized trialsDrug AdministrationContemporary management paradigmTherapyTrial dataTrial designLowered riskTherapeutic designTherapeuticsVenetoclaxBCL2 inhibition for multiple myeloma and AL amyloidosis
Cani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025, 206: 1285-1296. PMID: 40090369, DOI: 10.1111/bjh.20046.Peer-Reviewed Original ResearchMultiple myelomaAL amyloidosisBCL2 inhibitorsLight-chain (ALTreatment landscape of MMPlasma cell disorderMalignant blood disordersDevelopment of novel treatmentsBCL2 inhibitionTreatment landscapeDose optimizationCell disordersPatient selectionClinical studiesBlood disordersNovel treatmentAmyloidosisBCL2Light chainMyelomaToxicity concernsPatientsInhibitorsDrugTreatmentEfficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
Jaime-Casas S, Zugman M, Barragan-Carrillo R, Zang P, Ebrahimi H, Mercier B, Castro D, Yip W, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials. Journal Of Clinical Oncology 2025, 43: 813-813. DOI: 10.1200/jco.2025.43.5_suppl.813.Peer-Reviewed Original ResearchAny-grade adverse eventsAdvanced urothelial carcinomaObjective-response rateAntibody-drug conjugatesCombination regimensClinical trialsCheckpoint inhibitorsSafety/tolerability profileCombination therapyPublished prospective clinical trialsProspective clinical trialPeer-reviewed clinical trialsSystematic review of clinical trialsReview of clinical trialsRandom-effects modelEnfortumab vedotinSacituzumab govitecanUrothelial carcinomaProspective trialsTreatment landscapeMaculopapular rashEfficacy outcomesRetrospective studyToxicity profileCase report
2024
A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies
Swallow M, Edelson R, Girardi M. A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies. Clinics In Dermatology 2024, 43: 170-176. PMID: 39694197, DOI: 10.1016/j.clindermatol.2024.12.006.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaMycosis fungoidesSubtype of cutaneous T-cell lymphomaPathogenesis of cutaneous T-cell lymphomaNon-Hodgkin's lymphomaEvolving treatment landscapeSezary syndromeHistological variantsTreatment landscapeLymph nodesSchool of MedicineLymphomaYale School of MedicineFungoidesClinical careMalignancyLymphMycosisSyndromeSubtypesPathogenesisDifficult to Treat Depression: Focus on Approach, Algorithms, and Access.
Karp J, Brinton R, Fournier J, Harding L, Jha M, Lenze E, Mathew S, Meltzer-Brody S, Mohr D, Riva-Posse P, Wiechers I, Williams N. Difficult to Treat Depression: Focus on Approach, Algorithms, and Access. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39630090, DOI: 10.4088/jcp.psprmdd2408ah.Peer-Reviewed Original ResearchConceptsTreating depressionSpectrum of clinical severityTreatment of depressionEvolving treatment landscapeDepartment of PsychiatryBurden of depressionOral pharmacotherapyTreatment landscapeAdult patientsClinical severityCommunity health agenciesDepressionIncreased prevalenceHealth care systemPatientsDepression carePsychiatric workforcePsychiatryPatient advocatesCare systemTherapeutic engineeringHealth agenciesTelemedicine platformDo IRemissionChemotherapy and Targeted Therapies, Biological Therapies for Renal Cell Carcinoma
Malhotra J, Meza L, Govindarajan A, Pal S. Chemotherapy and Targeted Therapies, Biological Therapies for Renal Cell Carcinoma. 2024, 1-15. DOI: 10.1007/978-3-030-51192-0_98-1.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaOverall survivalTreatment landscapeCell carcinomaTargeted therapyTreatment landscape of metastatic renal cell carcinomaSystemic therapyCombination therapyBiologic therapyTreatment optionsTherapyCarcinomaTreatmentSurvivalMonotherapyImmunotherapyChemotherapyTrends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
Hanin A, Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Wainwright M, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L. Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia 2024, 65: e148-e155. PMID: 38837761, DOI: 10.1111/epi.18014.Peer-Reviewed Original ResearchNew-onset refractory status epilepticusSecond-line immunotherapyKetogenic dietStatus epilepticusDuration of status epilepticusRefractory status epilepticusStatus epilepticus onsetManagement of patientsEvolving treatment landscapeTreatment landscapeImmunotherapyConsensus recommendationsInterim analysisPatientsPatient outcomesAnakinraEpilepticusShort durationMedianORCIDietDaysTocilizumabIncreased useUnlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.
Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society Of Clinical Oncology Educational Book 2024, 44: e431766. PMID: 38828973, DOI: 10.1200/edbk_431766.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesTumor sitePredictive biomarkersAntigen expressionLack of robust predictive biomarkersSelection of targeted therapiesRobust predictive biomarkersTarget antigen expressionTumor antigen expressionCancer treatment landscapeBiomarkers of responseImprove patient selectionTumor intrinsic featuresBiomarkers of safetyUnique adverse eventsIdentification of patientsPopulation of patientsClinically actionable biomarkersSmall-molecule agentsPatient-centred outcomesTreatment landscapeBiomarker-drivenTreatment resistanceClinical benefitPatient selectionUnderstanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel Targeted TherapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscapeRisk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset
Hu J, Chandler M, Manuel C, Caicedo J, Denne M, Ewenstein B, Mokdad A, Xing S, Recht M. Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset. Journal Of Blood Medicine 2024, 15: 191-205. PMID: 38699197, PMCID: PMC11063465, DOI: 10.2147/jbm.s443380.Peer-Reviewed Original ResearchIntracranial hemorrhageIncidence rateInhibitor statusHemophilia AEstimate hazard ratiosAssociated with intracranial hemorrhageIncidence of intracranial hemorrhageMedian follow-up timeRisk of intracranial hemorrhageCurrent treatment landscapeIntracranial hemorrhage riskFollow-up timeTime-to-event analysisYears of ageProphylaxis statusHazard ratioTreatment landscapeGreater riskHepatitis CProphylactic treatmentPWHARate of mortalityIncreased riskRisk factorsATHNdatasetA Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Celik M, Gold M, Fuehrlein B. A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. Brain Sciences 2024, 14: 294. PMID: 38539681, PMCID: PMC10969323, DOI: 10.3390/brainsci14030294.Peer-Reviewed Original ResearchAlcohol use disorderUse disorderTreatment of alcohol use disordersGLP-1 receptor agonistsCurrent treatment landscapeAlcohol withdrawal syndromePhosphodiesterase-4 inhibitorWithdrawal syndromeTreatment landscapeReceptor agonistsTreatment modalitiesGlobal disease burdenPhosphodiesterase-4GLP-1Disease burdenNarrative reviewDisordersAnnual deathsMedicationTreatmentAlcoholPsychotherapyPsychedelicsHealth conditionsHeart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
Desai N, Olewinska E, Famulska A, Remuzat C, Francois C, Folkerts K. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Failure Reviews 2024, 29: 631-662. PMID: 38411769, PMCID: PMC11035416, DOI: 10.1007/s10741-024-10385-y.Peer-Reviewed Original ResearchRandomized Controlled TrialsHeart failureUnmet medical needAssociated with considerable morbidityDisease burdenPatient outcomesSymptomatic HF patientsEconomic burdenOverview of heart failureComposite cardiovascular deathClinical practice guidelinesGlobal healthcare concernMedical needPoor patient outcomesTargeted literature reviewPreventable disease burdenTreatment landscapeHFmrEF/HFpEFHF hospitalizationHF patientsCardiovascular deathElectronic databasesPatient characteristicsStudy characteristicsMortality riskThe Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa S, Jansen C, Jani Y, Evans S, Zhuang T, Brown J, Nazha B, Master V, Bilen M. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker Insights 2024, 19: 11772719241254179. PMID: 38827239, PMCID: PMC11143877, DOI: 10.1177/11772719241254179.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsResponse to immunotherapyAdverse eventsTreatment of genitourinary malignanciesImmune checkpoint blockadeSelection of therapySignificant side effectsCheckpoint blockadeCheckpoint inhibitorsGU malignanciesGenitourinary malignanciesPatient tumorsTreatment landscapeReview of biomarkersGenitourinary cancersGU tumorsPreclinical studiesPrognostic toolSide effectsTherapyBiomarker developmentTumorPatientsImmunotherapy
2023
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Aggarwal S, Espinosa S. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2023, 21: 1224-1233. PMID: 38081139, DOI: 10.6004/jnccn.2023.0062.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN guidelinesNCCN Guidelines InsightsSystemic therapy recommendationsAdvanced cervical cancerMetastatic diseaseTreatment landscapeClinical outcomesDiagnostic workupHistopathologic classificationTherapy recommendationsCancerMolecular profileAspects of managementRecent updatesDiagnostic featuresGuidelinesWorkupStagingDiseaseRecurrentPathologyUnderstanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
Majem M, Basch E, Cella D, Garon E, Herbst R, Leighl N. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. Lung Cancer 2023, 187: 107419. PMID: 38070301, DOI: 10.1016/j.lungcan.2023.107419.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage diseaseHealth-related qualityClinical trialsEarly-stage non-small cell lung cancerTreatment-related adverse effectsAppropriate HRQoL instrumentNSCLC clinical trialsCell lung cancerLong-term treatmentLung cancer clinical trialsCancer clinical researchCancer clinical trialsAdjuvant treatmentAdvanced diseaseHRQOL assessmentTreatment landscapeDisease recurrenceHRQoL instrumentsLung cancerDisease progressionLife measuresHRQoLNarrative reviewHealthcare professionalsNCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapyManagement of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia
Bewersdorf J, Zeidan A. Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. 2023, 119-128. DOI: 10.1007/978-981-99-3810-0_8.ChaptersTherapy-related AMLAcute myeloid leukemiaSecondary AMLAML-MRCMyeloid leukemiaRandomized phase III clinical trialsPhase III clinical trialsAdverse cytogenetic featuresOverall survival benefitDe novo AMLT-AML patientsYears of ageHigh-risk mutationsInduction chemotherapyMonosomal karyotypeCPX-351Intensive chemotherapyNovo AMLSurvival benefitTreatment landscapeAdverse prognosisFrontline treatmentSubgroup analysisClinical trialsConventional chemotherapyEGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
Liu S, Elkins I, Feldman J, Goldberg S. EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists. Oncology And Therapy 2023, 11: 419-431. PMID: 37750968, PMCID: PMC10673799, DOI: 10.1007/s40487-023-00242-7.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerCell lung cancerBiomarker testingLung cancerEGFR mutationsTreatment landscapeNon-smallIndividual patientsPatientsCancerBiomarkersHealthcare professionalsOncologistsBiomarker informationTreatmentPatient perspectiveBiopsyEGFRTherapyPatient advocatesReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaReal-world adherenceRefractory chronic lymphocytic leukemiaTyrosine kinase inhibitorsLymphocytic leukemiaB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsNovel oral agentsClinical trial dataOral agentsClinical characteristicsElderly patientsTreatment landscapeTreatment initiationReal-world findingsHigh adherenceMedicare beneficiariesLower discontinuationTrial dataDiscontinuationPatientsOlder adultsKinase inhibitorsAdherenceLeukemiaGenomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Ravi A, Hellmann M, Arniella M, Holton M, Freeman S, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin A, Vokes N, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde P, Anagnostou V, Riess J, Gibbons D, Pennell N, Velcheti V, Digumarthy S, Mino-Kenudson M, Califano A, Heymach J, Herbst R, Brahmer J, Schalper K, Velculescu V, Henick B, Rizvi N, Jänne P, Awad M, Chow A, Greenbaum B, Luksza M, Shaw A, Wolchok J, Hacohen N, Getz G, Gainor J. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics 2023, 55: 807-819. PMID: 37024582, PMCID: PMC10181943, DOI: 10.1038/s41588-023-01355-5.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerLung cancerAnti-PD-1/PD-L1 agentsCheckpoint blockade responsePD-L1 agentsTumor intrinsic subtypesCheckpoint inhibitorsCheckpoint blockadeTreatment landscapeImmunotherapy outcomesBlockade responseCohortBiological determinantsGenomic subgroupsEnhanced responseMolecular featuresWhole exomeCancerProminent associationOutcomesAssociationResponseNumber of associations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply